RS-2023-00283610

Autologous 4th generation GPC3 CAR-T clinical study for advanced hepatocellular carcinoma

Eutilex Co., Ltd.

Eutilex Co., Ltd.

ONCOLOGY | **Phase 1**

Product Type	4th generation CAR-T
Indication	Hepatocellular carcinoma
Target	Glypican-3 (GPC3)
MoA(Mechanism of Action)	307 recognizes tumor specific antigen GPC3 and directly kills the target tumor cells. IL18 produced in activated CAR-T plays a role in increasing the activity of CAR-T and reducing tumor-promoting cells. 
Competitiveness	• **4th generation CAR (IL18)** IL18 increases the function of CAR-T by binding to CAR-T by the autocrine and pracrine methods. IL18 affects immunosuppressive cells and tumor-promoting cells, reducing their cell function and cell number. • **T cell differentiation** T cell differentiation has a very close relationship between clinical results and cell phenotypes. Less differentiated T cells (Naive, Tscm, Tcm) show very high proliferation and anticancer efficacy. The manufacturing process of Eutilex shows a high less differentiated T cell rate.
Development Stage	Phase 1
Route of Administration	Intravenous administration, Single dose

kddf_bd@kddf.org
KDDF Business Development Team

KDDF Korea Drug Development Fund